AB Science (OTCMKTS:ABSCF) is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the discovery and development of protein kinase inhibitors. Its core focus is on the design of orally administered small-molecule therapies that target key signaling pathways involved in oncology, inflammatory disorders and neurodegenerative diseases. The company’s lead asset, masitinib, is a selective tyrosine kinase inhibitor that has been evaluated in multiple Phase 2 and Phase 3 clinical trials, including studies in mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and severe asthma.
Since its founding in 2001 by Dr. Alain Moussy and Dr. Jean-Christophe Chamoux, AB Science has built a diversified pipeline of clinical candidates. In addition to masitinib, the portfolio includes second-generation kinase inhibitors aimed at improving safety and efficacy profiles. The company conducts much of its research and development in France, while collaborating with academic institutions and clinical sites across Europe, North America and Asia to advance its programs through the regulatory process.
AB Science operates through subsidiaries and affiliates in key markets, including the United States, Italy and Germany, to support international clinical trials and prepare for potential commercialization. Beyond human therapeutics, the company has also explored veterinary applications of its kinase inhibitors, reflecting a commitment to leveraging its platform technology across multiple therapeutic areas.
Leadership at AB Science remains closely tied to its scientific founders, with Dr. Alain Moussy serving as Chief Executive Officer and Chairman of the Board. Guided by a management team combining drug development expertise and commercial strategy, the company continues to pursue partnerships and regulatory interactions to advance its late-stage programs toward potential approval and patient access.
